Sustainability
The immunization of animals and the extraction of animal sera is a practice that was initially conceived by Emil von Behring in the year 1890 and has been around ever since.
However, new technologies today allow to generate antibodies without the use of immunized animals. The Nobel Prize honoured technology of Antibody Phage Display allows to select antibodies entirely in vitro.
By using our sequence defined recombinant antibodies, you can obtain superior quality of your results with animal-free reagents.
It is our mission and aspiration every single day to achieve this goal, both for a sustainable future and medical safety of this and every future generation to come.
1Bradbury A, Plückthun A. (2015). Getting to reproducible antibodies: the rationale for sequenced recombinant characterized reagents. Protein Eng Des Sel. 28(10):303–305.
2Berglund L et al. (2008). A genecentric Human Protein Atlas for expression profiles based on antibodies. Mol Cell Proteomics 7(10):2019-2027.
3Bradbury A, Plückthun A. (2015). Reproducibility: Standardize antibodies used in research. Nature 518(7537):27-29.
4Dove A. (2017). Technology Feature | Agreeable antibodies: Antibody validation challenges and solutions. Science 357(6356):1165-1167.
5Goodman, 2018. The antibody horror show: an introductory guide for the perplexed. New Biotechnol 45:9-13.
6Bradbury A, Plückthun A. (2015). Antibodies: Validate recombinants once. Nature 520(7547):295.
7Taussig MJ et al. (2018). Antibody validation: a view from the mountains. N Biotechnol 45:1-8.
8Bradbury et al. (2018). When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regions. MAbs 10(4):539-546.
9Moutel et al. (2009). A multi-Fc-species system for recombinant antibody production. BMC Biotechnology 9:14.